US EditionJohnson and Johnson warns pharma tariffs could cause drug shortages
- President Trump's new tariff policies, announced Tuesday, prompted industry concerns about rising costs.
- Trump's administration began a probe into pharmaceutical imports' national security effects, potentially leading to duties.
- The tariffs impact medical devices and pharmaceuticals, industries with supply chains across Europe and Asia.
- J&J CFO Wolk stated they included about $400 million in expected tariff costs in their financial guidance.
- Tariffs could disrupt supply chains and cause shortages, according to J&J CEO Joaquin Duato.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
All
Left
4
Center
7
Right
2
Johnson & Johnson worried about losses from China tariffs despite projecting $700 million in profits
Johnson & Johnson's CEO said President Trump's tariffs on pharmaceuticals could cause a problem for drug supply chains.During an investor call, CEO Joaquin Duato told his colleagues that they should work with the Trump administration to address supply chain vulnerabilities that could arise as a result of tariffs.The remarks were seemingly an effective call for the Trump administration to ease tariffs on raw ingredients and drugs from China, the …
·United States
Read Full Article
Coverage Details
Total News Sources20
Leaning Left4Leaning Right2Center7Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 31%
C 54%
15%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
